Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
Sponsor: Yale University
Summary
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.
Official title: Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2025-02-20
Completion Date
2026-05
Last Updated
2026-01-27
Healthy Volunteers
No
Conditions
Interventions
Taltz
Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
Locations (1)
Yale New Haven Hospital
New Haven, Connecticut, United States